Bosulif

Drugs - Bosulif (bosutinib) [Pfizer]

February 2013

Therapeutic area - Oral Oncology

Approval criteria

• Diagnosis of chronic myelogenous leukemia AND
• Trial of imitinib AND
• Trial of dasatinib OR nilotinib

Quantity limits

The initial PA will allow a first fill of 14 days [fourteen, 500mg tablets and fifty-six 100 mg tablets] with one refill to ensure patient tolerance with therapy before approving in larger, monthly quantities.

• 500 mg = 34 per month
• 100 mg = 136 per month

Background information

BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. Prior therapy options include imitinib, dasatinib and nilotinib.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411